Cited by 339Single-cell and spatial transcriptomicsMyeloproliferative Neoplasms: Diagnosis and TreatmentCancer Genomics and Diagnostics

Somatic mutations and cell identity linked by Genotyping of Transcriptomes

Open access
Nam, Anna S., Kim, Kyu-Tae, Chaligne, Ronan, Izzo, Franco, Ang, Chelston, Taylor, Justin, Myers, Robert M., Abu-Zeinah, Ghaith +16 more·2019·Nature

Published version of a preprint

Abstract

Defining the transcriptomic identity of malignant cells is challenging in the absence of surface markers that distinguish cancer clones from one another, or from admixed non-neoplastic cells. To address this challenge, here we developed Genotyping of Transcriptomes (GoT), a method to integrate genotyping with high-throughput droplet-based single-cell RNA sequencing. We apply GoT to profile 38,290 CD34+ cells from patients with CALR-mutated myeloproliferative neoplasms to study how somatic mutations corrupt the complex process of human haematopoiesis. High-resolution mapping of malignant versus normal haematopoietic progenitors revealed an increasing fitness advantage with myeloid differentiation of cells with mutated CALR. We identified the unfolded protein response as a predominant outcome of CALR mutations, with a considerable dependency on cell identity, as well as upregulation of the NF-κB pathway specifically in uncommitted stem cells. We further extended the GoT toolkit to genotype multiple targets and loci that are distant from transcript ends. Together, these findings reveal that the transcriptional output of somatic mutations in myeloproliferative neoplasms is dependent on the native cell identity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1367-0

Cites

92 of 92 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cell hashing enabled multiplexing baseline and IFNa-treated samples into the same scRNA-seq reactions via time-point specifying barcoded antibodies, to obviate technical batch effects between serial samples.

    “We further incorporated cell hashing 24 that enabled multiplexing baseline and IFNa-treated samples into the same scRNA-seq reactions via time-point specifying barcoded antibodies, to obviate technical batch effects between serial samples ( Fig. 1b ).”

    From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [24]

    The Methods section on Genotyping of Transcriptomes describes cell barcodes used to link genotypes with transcriptomes, not antibody-based cell hashing. Searches for cell hashing, time-point-specific barcoded antibodies, and baseline versus IFNa-treated sample multiplexing found no passage addressing the cited claim. (LLM, conf=0.76)

    Experimental — accuracy not yet measured
  • Time-point specifying barcoded antibodies were incorporated to combine serial samples from the same individuals into a single experiment to remove technical batch effects.

    “we incorporated time-point specifying barcoded antibodies 24 to combine serial samples from the same individuals into a single experiment to remove technical batch effects”

    From Type 1 interferon perturbates clonal competition by reshaping human blood development (2026) · cites this paper as [24]

    The Methods sections on GoT and Circularization GoT describe cell barcodes, sample indexes, and barcoded cDNA, but not time-point-specific barcoded antibodies. A search for antibody-based labeling of serial samples and removal of batch effects found no passage in our copy addressing that procedure. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nam, A. S., Kim, K.-T., Chaligne, R., Izzo, F., Ang, C., Taylor, J., Myers, R. M., Abu-Zeinah, G., Brand, R., Omans, N. D., Alonso, A., Sheridan, C., Mariani, M., Dai, X., Harrington, E., Pastore, A., Cubillos-Ruiz, J. R., Tam, W., Hoffman, R., Rabadan, R., Scandura, J. M., Abdel-Wahab, O., Smibert, P., & Landau, D. A.
Affiliations
  • New York Genome Center (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • Weill Cornell Medicine (US)
  • Oxford Nanopore Technologies (United Kingdom) (GB)
  • Tisch Cancer Institute (US)
Corresponding author
Landau, Dan A.
Venue
Nature
Published
2019-07-03
Volume
571
Issue
7765
Pages
355-360
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2954384525
Cited by
333
References
92
Citations by year
2026: 35 · 2025: 54 · 2024: 59 · 2023: 41 · 2022: 44 · 2021: 49 · 2020: 36 · 2019: 13 · 2018: 2
FWCI
11.74
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
  • Burroughs Wellcome Fund
  • Brigham and Women's Hospital
  • National Institutes of Health (1dp2ca239065-01, 5r01ca229902-05, UL1TR002384)
  • Stand Up To Cancer
  • National Heart, Lung, and Blood Institute (R01HL145283, P01HL053762)
  • National Cancer Institute (DP2-CA239065, U54CA193313, R01-CA229902, P30CA008748, P01CA108671)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Health Sciences › Medicine › Genetics › Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
somatic mutations, cell identity, CALR mutation, myeloproliferative neoplasms, hematopoiesis, unfolded protein response, NF-κB signaling, myeloid differentiation, clonal fitness, single-cell RNA sequencing, droplet-based sequencing
MeSH terms
Animals, Cell Line, Clone Cells, Endoribonucleases, Genotype, Hematopoiesis, Hematopoietic Stem Cells, Humans, Models, Molecular, Mutation, Myeloproliferative Disorders, Neoplasms, Neoplastic Stem Cells, NF-kappa B, Protein Serine-Threonine Kinases, Sequence Analysis, RNA, Antigens, CD34, Calreticulin, Cell Proliferation, Mice, Primary Myelofibrosis, Unfolded Protein Response, Single-Cell Analysis, High-Throughput Nucleotide Sequencing, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review